No­vo clears Phase 3 he­mo­phil­ia A tri­al, plans to sub­mit ap­pli­ca­tion by year's end

No­vo Nordisk said Mon­day that its in­ves­ti­ga­tion­al treat­ment met both pri­ma­ry end­points in an open-la­bel Phase 3a study in pa­tients with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.